人活检和未活检囊胚的大容量玻璃化：一种简单、可靠的冷冻保存技术。
Large-volume vitrification of human biopsied and non-biopsied blastocysts: a simple, robust technique for cryopreservation.
作者信息
Reed Michael L, Said Al-Hasen, Thompson Douglas J, Caperton Charles L
机构信息
Center for Reproductive Medicine of New Mexico, 201 Cedar Street SE, Suite S1-20, Albuquerque, NM, 87106, USA,
出版信息
J Assist Reprod Genet. 2015 Feb;32(2):207-14. doi: 10.1007/s10815-014-0395-9. Epub 2014 Dec 3.
PURPOSE
To evaluate the transition from a proven slow-cooling cryopreservation method to a commercial large-volume vitrification system for human blastocysts.
METHODS
Retrospective analysis of de-identified laboratory and clinical data from January 2012 to present date for all frozen embryo replacement (FET) cycles was undertaken. Cryopreservation of trophectoderm-biopsied or non-biopsied blastocysts utilized during this time period was logged as either slow-cooling, small-volume vitrification, or large-volume vitrification. Blastocyst survival post-warm or post-thaw, clinical pregnancy following FET, and implantation rates were identified for each respective cryopreservation method.
RESULTS
Embryo survival was highest for large-volume vitrification compared to micro-volume vitrification and slow-cooling; 187/193 (96.9 %), 27/32 (84.4 %), and 244/272 (89.7 %), respectively. Survival of biopsied and non-biopsied blastocysts vitrified using the large-volume system was 105/109 (96.3 %) and 82/84 (97.6 %), respectively. Survival for micro-volume biopsied and non-biopsied blastocysts was 16/30 (83.3 %) and 2/2 (100.0 %) respectively. Slow-cooling post-thaw embryo survival was 272/244 (89.7 %). Clinical pregnancy and implantation rates outcomes for non-biopsied embryos were similar between large-volume and slow-cooling cryopreservation methods, 18/39 (46.2 %) clinical pregnancy and 24/82 (29.3 %) implantation/embryo, and 52/116 (44.8 %) clinical pregnancy and 67/244 (27.5 %) implantation/embryo, respectively. Comparing outcomes for biopsied embryos, clinical pregnancy and implantation rates were 39/67 (58.2 %) clinical pregnancy and 50/105 (47.6 %) implantation/embryo and 4/16 (25 %) clinical pregnancy and 6/25 (24.0 %) implantation/embryo, respectively.
CONCLUSIONS
The LifeGlobal large-volume vitrification system proved to be very reliable, simple to learn and implement in the laboratory. Clinically large-volume vitrification was as, or more effective compared to slow-cooling cryopreservation in terms of recovery of viable embryos in this laboratory.
目的
评估从一种已证实的慢速冷冻保存方法转换为用于人类囊胚的商业大容量玻璃化系统的效果。
方法
对2012年1月至今所有冷冻胚胎移植（FET）周期的匿名实验室和临床数据进行回顾性分析。在此期间，对经滋养外胚层活检或未经活检的囊胚进行冷冻保存的记录分为慢速冷冻、小容量玻璃化或大容量玻璃化。确定每种冷冻保存方法的解冻后囊胚存活率、FET后的临床妊娠率和着床率。
结果
与小容量玻璃化和慢速冷冻相比，大容量玻璃化的胚胎存活率最高；分别为187/193（96.9%）、27/32（84.4%）和244/272（89.7%）。使用大容量系统玻璃化的活检和未活检囊胚的存活率分别为105/109（96.3%）和82/84（97.6%）。小容量活检和未活检囊胚的存活率分别为16/30（83.3%）和2/2（100.0%）。解冻后慢速冷冻的胚胎存活率为272/244（89.7%）。大容量和慢速冷冻保存方法在未活检胚胎的临床妊娠和着床率方面结果相似，分别为18/39（46.2%）临床妊娠和24/82（29.3%）着床/胚胎，以及52/116（44.8%）临床妊娠和67/244（27.5%）着床/胚胎。比较活检胚胎的结果，临床妊娠和着床率分别为39/67（58.2%）临床妊娠和50/105（47.6%）着床/胚胎以及4/16（25%）临床妊娠和6/25（24.0%）着床/胚胎。
结论
LifeGlobal大容量玻璃化系统被证明非常可靠，在实验室中易于学习和实施。在本实验室中，就存活胚胎的回收率而言，临床上大容量玻璃化与慢速冷冻保存方法一样有效，甚至更有效。
Zotero 插件